Fetal red cell and platelet antigen genotyping: progress and pitfalls
Non-invasive fetal genotyping has greatly improved the care of pregnancies at risk of haemolytic disease of the newborn, with mass screening also being cost-effective for targeted anti-D prophylaxis. Edwin Massey and colleagues provide an overview.
This story is Premium Content and is only available to registered users. Please log in to view the full text. If you don't already have an account, please register with us completely free of charge.